Is Brooks Laboratories the Best Stock in Its Sector? A Look at the Numbers

Brooks Laboratories CMP Rs 61 (24 Sep 2026). Market cap Rs 180 Cr. ROE 4.80%. P/E 39.53x versus Industry P/E 51.57x.

Updated: 24 Sept 2026 • 12:31 pm

Posted by:

Is Brooks Laboratories the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Brooks Laboratories is one of the names investors compare when screening the Healthcare sector, built on a 4.80% return on equity and a P/E of 39.53x against an Industry P/E of 51.57x. Whether Brooks Laboratories is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Brooks Laboratories the best stock in its sector? The stock trades on the NSE at Rs 61 as of 24 September 2026, within its 52-week range of Rs 36.30 to Rs 152.39. Brooks Laboratories Ltd manufactures sterile injectable and ophthalmic pharmaceutical formulations.

Brooks Laboratories sits in the Healthcare sector, and its 4.80% ROE and 39.53x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Brooks Laboratories

Brooks Laboratories Ltd manufactures sterile injectable and ophthalmic pharmaceutical formulations. It manufactures sterile injectable and ophthalmic pharmaceutical formulations, and the stock has pulled back sharply from its 52-week high over the past year. At a market capitalisation of Rs 180 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Brooks Laboratories the Best Stock in Its Sector?

Brooks Laboratories makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 4.80% ROE with a 39.53x P/E against the sector's 51.57x Industry P/E. Brooks Laboratories' 39.53x P/E is below the 51.57x Industry P/E, though its 4.80% ROE trails Bal Pharma's in this comparison, and the stock has fallen sharply from its 52-week high over the past year.

Metric	Brooks Laboratories
CMP (NSE)	Rs 60.97
52-Week High / Low	Rs 152.39 / Rs 36.30
Market Cap	Rs 180 Cr
P/E (TTM) vs Industry P/E	39.53x vs 51.57x
P/B	1.49
ROE	4.80%
EPS (TTM)	Rs 1.55
Dividend Yield	0.00%
Debt to Equity	0.07

Compare Brooks Laboratories Against Other Healthcare Sector Stocks

How Brooks Laboratories Compares Against Its Healthcare Sector Peers

The table below sets Brooks Laboratories against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Brooks Laboratories	180	39.53	4.80%	0.07
Bal Pharma	172	23.72	7.64%	1.94
Beta Drugs	2,425	52.41	16.95%	0.60
Peer average (2 companies)	-	38.06	12.29%	1.27

Against this peer set, Brooks Laboratories's 4.80% ROE is below the 12.29% peer average, and its P/E of 39.53x runs above the peer average of 38.06x. Brooks Laboratories' 39.53x P/E is below the 51.57x Industry P/E, though its 4.80% ROE trails Bal Pharma's in this comparison, and the stock has fallen sharply from its 52-week high over the past year.

What Makes Brooks Laboratories Worth Watching in Healthcare

Below Industry P/E: A 39.53x P/E against a 51.57x Industry P/E is a discount relative to the Healthcare sector.
Low leverage: A debt to equity ratio of 0.07 is manageable for a sterile formulations manufacturer.
Sterile injectable and ophthalmic manufacturing: Manufacturing sterile injectable and ophthalmic formulations positions Brooks Laboratories in a more specialised, higher-barrier segment of pharma manufacturing.

Brooks Laboratories Valuation: Is It Justified?

Brooks Laboratories' 39.53x P/E is below the 51.57x Industry P/E, though its 4.80% ROE trails Bal Pharma's in this comparison, and the stock has fallen sharply from its 52-week high over the past year. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Billionbrains Garage Ventures the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Brooks Laboratories and other Healthcare sector stocks.

How to Track Brooks Laboratories Before You Invest

Before deciding whether Brooks Laboratories deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Brooks Laboratories to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Brooks Laboratories earns a place in the best stock in its sector conversation on the strength of a 4.80% ROE and a P/E of 39.53x against a 51.57x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Brooks Laboratories the best stock in its sector?

Ans. Brooks Laboratories has a 4.80% ROE and trades at 39.53x P/E against a 51.57x Industry P/E, and compares below the peer average ROE of 12.29% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Brooks Laboratories?

Ans. Brooks Laboratories was trading at Rs 60.97 on the NSE as of 24 September 2026, within its 52-week range of Rs 36.30 to Rs 152.39.

What sector does Brooks Laboratories belong to?

Ans. Brooks Laboratories is classified under the Healthcare sector on Univest.

How does Brooks Laboratories compare to its sector peers on P/E?

Ans. Brooks Laboratories's P/E of 39.53x is above the 38.06x average of the 2 named peers compared in this article.

What is Brooks Laboratories's return on equity?

Ans. Brooks Laboratories reported a return on equity of 4.80%, which is below the 12.29% average of its named peers in this comparison.

Should I invest in Brooks Laboratories based on its sector position?

Ans. Brooks Laboratories's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.